Optimer Pharmaceuticals Provides Update on DIFICID Tablets Launch; DIFICID Treatments Shipped by Wholesalers Grew Almost 87% in Fourth Quarter of 2011
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today provided an update on commercial sales of DIFICID® (fidaxomicin) tablets since launching the antibacterial drug in July 2011 for the treatment of Clostridium difficile associated-diarrhea in adults 18 years of age or older in the United States.
For the three months ended December 31, 2011, Optimer estimates 4,675 DIFICID treatments were shipped from Optimer's wholesalers to hospital pharmacies, retail pharmacies and long-term care facilities, exceeding treatments sold by Optimer to its wholesalers over the same period. This is an increase of 86.6% when compared to the 2,505 treatments shipped from Optimer's wholesalers to hospital pharmacies, retail pharmacies and long-term care facilities for the period of July 19, 2011 through September 30, 2011. DIFICID treatments shipped from Optimer's wholesalers to hospital pharmacies, retail pharmacies and long-term care facilities grew at a compounded monthly growth rate of 11.3% for the quarter ended December 31, 2011.
Optimer recognizes product sales of DIFICID upon delivery of product to its wholesalers. For the period of July 19, 2011, the date of DIFICID's first sales, through December 31, 2011 Optimer estimates DIFICID gross sales of $24.4 million. Optimer estimates total DIFICID gross sales for the fourth quarter of 2011 of $12.2 million, compared to gross sales for the third quarter of 2011 of $12.1 million, which included $5.1 million in inventory stocking by Optimer's wholesalers. DIFICID wholesaler inventory levels at the end of the fourth quarter are estimated to have decreased by $1.1 million from the levels at the end of the third quarter, and remain within Optimer's target range of 14 to 28 days of demand.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.